[go: up one dir, main page]

WO2011056985A3 - Substituted heterocyclic compounds - Google Patents

Substituted heterocyclic compounds Download PDF

Info

Publication number
WO2011056985A3
WO2011056985A3 PCT/US2010/055467 US2010055467W WO2011056985A3 WO 2011056985 A3 WO2011056985 A3 WO 2011056985A3 US 2010055467 W US2010055467 W US 2010055467W WO 2011056985 A3 WO2011056985 A3 WO 2011056985A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
substituted heterocyclic
heterocyclic compounds
relates
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/055467
Other languages
French (fr)
Other versions
WO2011056985A2 (en
Inventor
Matthew Abelman
Nancy Chu
Robert Jiang
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of WO2011056985A2 publication Critical patent/WO2011056985A2/en
Publication of WO2011056985A3 publication Critical patent/WO2011056985A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I) as further described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
PCT/US2010/055467 2009-11-04 2010-11-04 Substituted heterocyclic compounds Ceased WO2011056985A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25813209P 2009-11-04 2009-11-04
US61/258,132 2009-11-04

Publications (2)

Publication Number Publication Date
WO2011056985A2 WO2011056985A2 (en) 2011-05-12
WO2011056985A3 true WO2011056985A3 (en) 2011-10-27

Family

ID=43416386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/055467 Ceased WO2011056985A2 (en) 2009-11-04 2010-11-04 Substituted heterocyclic compounds

Country Status (1)

Country Link
WO (1) WO2011056985A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
BR112013028886A2 (en) 2011-05-10 2016-08-09 Gilead Sciences Inc fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compound as ion channel regulator
CN102491979A (en) * 2011-12-21 2012-06-13 天津科技大学 1-hydroxyethyl-5-substituted indolone derivative and preparation method and application thereof
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
TW201623264A (en) 2014-03-29 2016-07-01 魯賓有限公司 Sulfonamide compounds as voltage gated sodium channel modulators
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
CA2984290C (en) 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
JP6800885B2 (en) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． Imidazopyrazine and pyrazolopyrimidine, and their use as AMPA receptor regulators
ES2865330T3 (en) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as AMPA receptor modulators
TW201722938A (en) 2015-09-04 2017-07-01 魯賓有限公司 Sulfonamide compounds as voltage-gated sodium channel modulators
DK3548033T3 (en) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc COMPOUNDS AND THEIR METHOD OF USE
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP3801535A4 (en) 2018-05-30 2022-03-02 Praxis Precision Medicines, Inc. Ion channel modulators
EA202092908A1 (en) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. ION CHANNEL MODULATORS
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CN116813525B (en) * 2023-08-28 2023-11-21 苏州爱玛特生物科技有限公司 Synthesis method of polyacetyl substituted oxindole compound

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049288A1 (en) * 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US20020042427A1 (en) * 2000-02-28 2002-04-11 Tang Peng Cho 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
WO2006113864A2 (en) * 2005-04-20 2006-10-26 Xenon Pharmaceuticals Inc. Oxindole compounds and their uses as therapeutic agents
EP1820795A1 (en) * 2004-12-07 2007-08-22 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
EP1860098A1 (en) * 2005-03-16 2007-11-28 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
WO2008138184A1 (en) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
JP2009023986A (en) * 2006-11-08 2009-02-05 Pharma Ip Biaryl derivatives as anticancer agents
WO2009045381A1 (en) * 2007-10-04 2009-04-09 Merck & Co., Inc. N-substituted oxindoline derivatives as calcium channel blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6462032B1 (en) * 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
WO2001049288A1 (en) * 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
US20020042427A1 (en) * 2000-02-28 2002-04-11 Tang Peng Cho 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
EP1820795A1 (en) * 2004-12-07 2007-08-22 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
EP1860098A1 (en) * 2005-03-16 2007-11-28 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
WO2006113864A2 (en) * 2005-04-20 2006-10-26 Xenon Pharmaceuticals Inc. Oxindole compounds and their uses as therapeutic agents
JP2009023986A (en) * 2006-11-08 2009-02-05 Pharma Ip Biaryl derivatives as anticancer agents
WO2008138184A1 (en) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases
WO2009045381A1 (en) * 2007-10-04 2009-04-09 Merck & Co., Inc. N-substituted oxindoline derivatives as calcium channel blockers

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALDO ANDREANI ET AL: "Potential antitumor agents XVII", ACTA PHARMACEUTICA NORDICA, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 2, no. 6, 1 January 1990 (1990-01-01), pages 407 - 414, XP000925899, ISSN: 1100-1801 *
ANDREW FENSOME ET AL: "New Progesterone Receptor Antagonists: 3,3-Disubstituted 5-Aryloxindoles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 12, 1 January 2002 (2002-01-01), pages 3487 - 3490, XP002418428, ISSN: 0960-894X, DOI: DOI:10.1016/S0960-894X(02)00746-1 *
DATABASE REGISTRY [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 September 2009 (2009-09-18), XP002641204, Database accession no. 1185575-32-9 *
FENSOME A ET AL: "Novel 5-Aryl-1,3-dihydro-indole-2-thiones: Potent, Orally Active Progesterone Receptor Agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 13, 1 January 2003 (2003-01-01), pages 1317 - 1320, XP002337380, ISSN: 0960-894X, DOI: DOI:10.1016/S0960-894X(03)00129-X *
GERHARD HIMBERT ET AL: "The thiophene nucleus as a diene or a dienophile in the intramolecular diels alder reaction of N-(2-thienyl)allene carboxamides", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1990 (1990-01-01), pages 405 - 406, XP009149266, ISSN: 0022-4936, DOI: DOI:10.1039/C39900000405 *
GIUSEPPE BARTOLI ET AL: "Intramolecular peterson olefination of ortho-trimethylsilylmethyl anilides: a new synthesis of N-methylindoles", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1988 (1988-01-01), pages 807 - 808, XP009149263, ISSN: 0022-4936 *
LAURA A. MCALLISTER, ROSEMARY A. MCCORMICK, STEPHEN BRAND, AND DAVID J. PROCTER: "A Fluorous-Phase Pummerer Cyclative-Capture Strategy for the Synthesis of Nitrogen Heterocycles", ANGEWANDTE CHEMIE, vol. 117, 2005, pages 456 - 459, XP002641203, DOI: 10.1002/ange.200461930 *
OFINO K: "Reactions of Substituted 1-Oxaspiro-and 1-Azaspiro-[3.5]nona-5,8-dien e-2,7-diones with Nucleophiles", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, CHEMICAL SOCIETY, GB, 1 January 1979 (1979-01-01), pages 1176 - 1181, XP009149265, ISSN: 0300-922X *

Also Published As

Publication number Publication date
WO2011056985A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2011056985A3 (en) Substituted heterocyclic compounds
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
EA026385B9 (en) Fused heterocyclic compounds as ion channel modulators
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
MX338916B (en) Oxazepines as ion channel modulators.
EA201290121A1 (en) Condensed Heterocyclic Compounds As Modulators of Ion Channels
MX2011012337A (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY164731A (en) Compound
EA201100503A1 (en) GLUCOSIDE DERIVATIVES AND THEIR APPLICATIONS
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
WO2011082266A3 (en) Substituted heterocyclic compounds
EA201200794A1 (en) TRIAZOLOPRYRIDINS
WO2011006935A3 (en) Tetrazole derivatives
EA200901133A1 (en) DERIVATIVES OF DIANILINOPYRIMIDINE AS KEEIN INHIBITORS WEE1, PHARMACEUTICAL COMPOSITION AND USE
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
MX2012002633A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes.
GEP201606513B (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
EA201270302A1 (en) ANHARROUND FORMS OF PYRIDINE DERIVATIVES
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
IN2011KN05169A (en)
EA201100502A1 (en) GLYCOSIDE DERIVATIVES AND THEIR APPLICATIONS
WO2011087712A3 (en) Tricyclic derivatives and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10776501

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10776501

Country of ref document: EP

Kind code of ref document: A2